Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $175.28 USD
Change Today -0.96 / -0.54%
Volume 1.5M
ALXN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for alexion pharmaceuticals inc (ALXN)

Alexion Pharmaceuticals, Inc. has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total $944.0M USD. Accounts Receivable are typical for the industry, with 69.83 days worth of sales outstanding. Last, Alexion Pharmaceuticals, Inc. is among the most efficient in its industry at managing inventories, with only 292.91 days of its Cost of Goods Sold tied up in inventory.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
Restated
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents540.9989.5529.9944.0
Short-Term Investments----985.01,017.6
TOTAL CASH AND SHORT TERM INVESTMENTS540.9989.51,514.91,961.6
Accounts Receivable244.3295.6421.8432.9
TOTAL RECEIVABLES244.3295.6421.8432.9
Inventory81.494.5102.6176.4
Prepaid Expenses32.057.484.4112.1
Deferred Tax Assets, Current19.126.141.435.7
Other Current Assets23.632.521.877.3
TOTAL CURRENT ASSETS941.31,495.62,186.92,796.0
Gross Property Plant and Equipment226.5245.6295.5513.6
Accumulated Depreciation-60.6-80.0-99.6-130.6
NET PROPERTY PLANT AND EQUIPMENT165.9165.6195.9383.0
Goodwill79.6253.6254.1254.1
Accounts Receivable, Long Term--21.3----
Deferred Tax Assets, Long Term103.914.03.434.9
Other Intangibles91.6646.7614.9596.3
Other Long-Term Assets12.516.762.5137.6
TOTAL ASSETS1,394.82,613.63,317.74,202.0
    
LIABILITIES & EQUITY    
Accounts Payable16.021.521.644.0
Accrued Expenses165.3181.4293.4300.4
Current Portion of Long-Term Debt/Capital Lease--48.048.048.0
Current Income Taxes Payable18.368.4108.994.8
Other Current Liabilities, Total10.29.556.760.7
Unearned Revenue, Current17.931.353.858.8
TOTAL CURRENT LIABILITIES227.8360.1582.4606.7
Long-Term Debt--101.065.09.5
Capital Leases----32.2107.1
Pension & Other Post-Retirement Benefits--8.5----
Deferred Tax Liability Non-Current0.019.8101.27.0
Other Non-Current Liabilities32.5153.3154.7169.6
TOTAL LIABILITIES260.3642.7935.6899.9
Common Stock0.00.00.00.0
Additional Paid in Capital1,261.61,852.22,106.22,592.2
Retained Earnings-128.6126.2379.11,036.0
Treasury Stock-2.7-14.2-80.4-383.0
Comprehensive Income and Other4.26.6-22.956.8
TOTAL COMMON EQUITY1,134.51,970.92,382.13,302.0
TOTAL EQUITY1,134.51,970.92,382.13,302.0
TOTAL LIABILITIES AND EQUITY1,394.82,613.63,317.74,202.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $175.28 USD -0.96

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,815 GBp -41.00
Dr Reddy's Laboratories Ltd 4,053 INR -156.35
Sigma-Aldrich Corp $139.56 USD 0.00
Symrise AG €52.66 EUR -0.55
United Therapeutics Corp $149.96 USD -3.79
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 60.2x
Price/Sales 14.9x
Price/Book 4.7x
Price/Cash Flow 67.3x
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.